EXETER, N.H., March 6, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), ('Vapotherm' or the 'Company') today announced that David Yamane, MD was awarded the Star Research Award by the Society for Critical Care Medicine (SCCM) at the 2024 Critical Care Congress. The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD..

新罕布什尔州埃克塞特，2024年3月6日/PRNewswire/--Vapotherm，Inc.（OTCQX:VAPO），（“Vapotherm”或“公司”）今天宣布，医学博士David Yamane在2024年重症监护大会上被重症监护医学会（SCCM）授予Star研究奖。该奖项是对HYPERACT研究的认可，HYPERACT研究是一项新的多中心随机对照试验，为临床医生治疗中重度COPD急性加重提供了一种额外的，更舒适的选择。。

(https://journals.lww.com/ccmjournal/citation/2024/01001/42__high_velocity_nasal_insufflation_vs.43.aspx)

（笑声）(https://journals.lww.com/ccmjournal/citation/2024/01001/42__high_velocity_nasal_insufflation_vs.43.aspx)（笑声）

This study compared non-invasive positive pressure ventilation (NiPPV) to Vapotherm high velocity therapy by measuring relief of dyspnea (breathlessness) as well as blood chemistry values and patient response.

本研究通过测量呼吸困难（呼吸困难）的缓解程度以及血液化学值和患者反应，比较了无创正压通气（NiPPV）与Vapotherm高速治疗。

Dr. Yamane shared his sentiments, stating, 'I am deeply honored by this recognition and genuinely excited about the potential impact of the HYPERACT study on health care. Offering an alternative to mask-based therapies that is both effective and comfortable for patients marks a significant advancement in our approach to COPD treatment.'.

亚曼博士分享了他的观点，他说：“我对这一认可深感荣幸，并对HYPERACT研究对医疗保健的潜在影响感到由衷兴奋。提供一种替代基于面罩的疗法，对患者既有效又舒适，标志着我们COPD治疗方法的重大进步。”。

Acute exacerbations of COPD contribute to over 600K emergency room (ER) visits and 140K deaths annually in the US alone. The cost is approximately $50 billion per year. (1,2)

仅在美国，COPD急性加重每年就导致超过60万急诊室（ER）就诊和14万人死亡。每年的成本约为500亿美元。（1,2）

This is the first multi-center, randomized, controlled trial focused on patients with moderate to severe exacerbations of COPD, showing similar improvement in pH and pCO2 comparing high velocity therapy and NiPPV.

这是第一项针对COPD中度至重度加重患者的多中心随机对照试验，与高速治疗和NiPPV相比，pH和pCO2的改善相似。

'When patients present to the emergency department out of breath, they're often placed on a mask-based therapy that uses pressure to open their airways. It can be even more distressing when you can't breathe to have a mask on your face, forcing air down your lungs' said Vapotherm's Chief Medical Officer, Jessica Whittle, MD, PhD.

“当患者上气不接下气地出现在急诊室时，他们通常会接受基于面罩的治疗，利用压力打开呼吸道。Vapotherm的首席医疗官、医学博士杰西卡·惠特尔（JessicaWhittle）说，当你无法呼吸，脸上戴着口罩，迫使空气进入肺部时，可能会更加痛苦。

'This study concludes that high velocity therapy provides similar clinical results and statistically superior patient reported comfort compared to mask-based therapies.'.

“这项研究得出结论，与基于面罩的疗法相比，高速疗法提供了相似的临床结果和统计学上优越的患者报告舒适度。”。

Over time, patients reported improved comfort on high velocity therapy while patients on NiPPV reported more discomfort from baseline. 19% of NiPPV patients failed therapy compared to 11% of high velocity therapy patients.

随着时间的推移，患者报告高速治疗的舒适度提高，而NiPPV患者报告的基线不适感增加。19%的NiPPV患者治疗失败，而高速治疗患者为11%。

Joe Army, Vapotherm's President and Chief Executive Officer expressed his enthusiasm, stating, '11% of patients on high velocity therapy in HYPERACT were effectively treated in the ED and were discharged home, whereas 0% of patients treated with NiPPV were discharged directly home – that's a huge cost savings for hospitals.' Mr.

Vapotherm总裁兼首席执行官乔·阿马里（JoeArmy）表示了他的热情，他表示，“11%接受HYPERACT高速治疗的患者在急诊室得到了有效治疗并出院回家，而接受NiPPV治疗的患者中有0%直接出院回家-这为医院节省了巨额成本。”先生。

Army continues, 'This is a win-win-win scenario: a win for the clinician to use a simple, evidence-based therapy, a win for the patient regarding comfort, and a win for the hospital because mask-based complications add costs.' (3).

陆军继续说，“这是一个双赢的场景：临床医生使用简单的循证治疗是一个胜利，病人在舒适方面是一个胜利，医院也是一个胜利，因为基于面罩的并发症会增加成本。”（3） 。

Dr. Yamane was presented with the award at the 2024 Critical Care Congress on January 23rd, 2024, in Phoenix, AZ. He also presented the HYPERACT findings at the conference.

亚曼博士于2024年1月23日在亚利桑那州凤凰城举行的2024年重症监护大会上获得了该奖项。他还在会议上介绍了HYPERACT的研究结果。

Sullivan J, Pravosud V, Mannino DM, Siegel K, Choate R, Sullivan T. National and state estimates of COPD morbidity and mortality - united states, 2014-2015. Chronic Obstr Pulm Dis. 2018;5(4):324-333. doi: 10.15326/jcopdf.5.4.2018.0157.

Sullivan J，Pravosud V，Mannino DM，Siegel K，Choate R，Sullivan T.2014-2015年美国COPD发病率和死亡率的国家和州估计。慢性阻塞性肺疾病。2018年；5（4）：324-333。doi:10.15326/jcopdf.5.4.2018.0157。

Nguyen PL, Uddin MM, Mir T, et al. Trends in incidence, and mortality of acute exacerbation of chronic obstructive pulmonary disease in the United States emergency department (2010–2018). COPD: Journal of Chronic Obstructive Pulmonary Disease. 2021;18(5):567-575. https://doi.org/10.1080/15412555.2021.1979500.

Nguyen PL，Uddin MM，Mir T等。美国急诊科慢性阻塞性肺疾病急性加重的发病率和死亡率趋势（2010-2018）。COPD：慢性阻塞性肺疾病杂志。2021年；18（5）：567-575。https://doi.org/10.1080/15412555.2021.1979500.

doi: 10.1080/15412555.2021.1979500..

doi:10.1080/15412555.2021.1979500。。

Carron M. et al. Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials. British Journal of Anaesthesia. 110(6):896-914. (2013) https://www.ncbi.nlm.nih.gov/pubmed/23562934

Carron M.等人，《无创通气技术的并发症：随机试验的全面定性回顾》。英国麻醉杂志。110（6）：896-914。（2013年）https://www.ncbi.nlm.nih.gov/pubmed/23562934

About Vapotherm

关于Vapotherm

Vapotherm, Inc. (OTCQX: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders.

Vapotherm，Inc.（OTCQX:VAPO）是一家上市的先进呼吸技术开发商和制造商，总部位于美国新罕布什尔州埃克塞特。该公司开发了创新，舒适，无创的技术，用于慢性或急性呼吸障碍患者的呼吸支持。

Over 4.2 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com..

使用Vapotherm high velocity therapy®系统治疗了420多万名患者。有关更多信息，请访问www.vapotherm.com。。

Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems' mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies.

Vapotherm高速治疗是无面罩的无创呼吸支持，是缓解呼吸窘迫（包括高碳酸血症，低氧血症和呼吸困难）的一线工具。它可以用一种工具快速，安全地治疗未分化的呼吸窘迫。HVT 2.0和Precision Flow systems的无面罩界面可提供最佳调节的呼吸气体，使患者感到舒适，并降低与面罩疗法相关的风险和护理复杂性。

While being treated, patients can talk, eat, drink and take oral medication..

在接受治疗时，患者可以说话、吃饭、喝水和口服药物。。

Legal Notice Regarding Forward-Looking Statements

关于前瞻性声明的法律通知

This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the Company's business and growth prospects in Brazil. In some cases, you can identify forward-looking statements by terms such as 'expect,' 'anticipate,' 'continue,' 'plan,' 'intend,' 'will,' or 'typically,' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates.

本新闻稿包含1995年《私人证券诉讼改革法案》下的前瞻性声明，包括有关该公司在巴西的业务和增长前景的声明。在某些情况下，您可以通过诸如“预期”、“预期”、“继续”、“计划”、“打算”、“意志”或“通常”等术语或这些术语的否定词或其他类似表达来识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语，并且使用了未来日期。

Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Other risks and uncertainties included under the heading 'Risk Factors' in Vapotherm's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and in its subsequent filings with the SEC.

每个前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果存在重大差异。Vapotherm于2024年2月22日向美国证券交易委员会提交的截至2023年12月31日财年的10-K表年度报告以及随后向美国证券交易委员会提交的文件中，标题为“风险因素”的其他风险和不确定性。

The forward-looking statements contained in this press release reflect Vapotherm's views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law..

本新闻稿中包含的前瞻性声明反映了Vapotherm截至本新闻稿发布之日的观点，Vapotherm不承担也明确否认任何义务更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。。

Investor Contact:John Landry, SVP and CFO

投资者联系人：高级副总裁兼首席财务官John Landry

http://investors.vapotherm.com/

http://investors.vapotherm.com/

SOURCE Vapotherm, Inc.

来源：Vapotherm公司。